InstalabLoading...
InstalabLoading...
If sickle cell disease runs in your family, or if you trace ancestry to Africa, the Mediterranean, the Middle East, or India, this is a number you should know about yourself before you have children. The result tells you whether you carry the sickle gene at all, and if so, whether you carry one copy (the silent trait) or two (the disease).
For someone already diagnosed, tracking the percentage of HbS (hemoglobin S) over time is the clearest signal of how well disease-modifying therapies and transfusions are doing their job. The number is not a curiosity. It changes decisions about medications, pregnancy planning, and lifelong monitoring.
HbS (hemoglobin S) is an abnormal version of the protein inside red blood cells that carries oxygen. It comes from a single change in the beta-globin gene that swaps one amino acid for another at position 6 of the protein chain. That tiny edit is enough to change how the protein behaves under low oxygen.
When HbS gives up its oxygen, the protein molecules stick together and form rigid strands inside the red cell. The cell warps into a stiff, crescent shape. These distorted cells break apart early (a process called hemolysis), get stuck in small blood vessels, and trigger pain, organ damage, and chronic anemia (low blood count).
You inherit the trait from your parents. One copy of the sickle gene plus one normal copy is called sickle cell trait (HbAS), which is usually silent. Two copies of the sickle gene, or one sickle gene plus another beta-globin variant like HbC or beta-thalassemia, produces sickle cell disease. The lab measures both whether HbS is present and what percentage of your total hemoglobin it represents, which is what distinguishes trait from disease.
People with two sickle gene copies (HbSS) or HbS combined with beta-zero thalassemia have the most severe form. The defining problems are chronic hemolytic anemia, sudden vaso-occlusive pain crises (when sickled cells block small blood vessels), acute chest syndrome (a lung emergency unique to this disease), stroke, repeated infections, and progressive damage to the kidneys, spleen, liver, and bones.
Lung complications are a leading cause of early death in sickle cell disease, including pulmonary hypertension (high pressure in the lung's blood vessels), blood clots in the lungs, and asthma-like disease. Even genotypes once considered milder, such as HbSE and HbS combined with delta-beta thalassemia, can produce severe events including stroke, acute chest syndrome, bone infarction, and death.
Higher levels of fetal hemoglobin (HbF, the form of hemoglobin you make as a baby) tend to dilute HbS and reduce sickling. People with naturally higher HbF, or those who raise their HbF through medication, generally have milder disease, fewer crises, better hemoglobin counts, and longer survival.
If you carry one sickle gene and one normal gene (HbAS), you almost certainly feel fine. Carrier status was favored by evolution in malaria-endemic regions because it offers protection against severe Plasmodium falciparum malaria, which is why HbS is common in sub-Saharan Africa, parts of India, the Middle East, and Mediterranean and American populations with these ancestries.
Trait status is generally benign, but it is not entirely without risk. Reviews note associations with certain complications including a small increase in the risk of blood clots and other vascular events. The most consequential reason to know your trait status is reproductive: if you and a partner both carry HbS, each pregnancy carries a one-in-four chance of producing a child with sickle cell disease.
In 2010, an estimated 5,476,000 babies were born worldwide carrying one sickle gene (HbAS), and about 312,000 were born with two copies (HbSS), with most cases concentrated in sub-Saharan Africa and India. A study in Botswana reported a local HbS allele frequency of 0.0094 in children, illustrating how prevalence varies even within high-risk regions.
In Portugal, sickle cell trait was the most common hemoglobinopathy detected on screening, showing that the gene has spread well beyond its original geographic origins. If you have ancestry from any of these regions, knowing your status is reasonable regardless of where you currently live.
HbS testing is reported as the percentage of total hemoglobin that is the sickle form, measured by techniques such as HPLC (high-performance liquid chromatography, a lab method that separates and measures different hemoglobin types) or hemoglobin electrophoresis (which separates them by electrical charge). Normal results show no HbS at all. The categories below are based on the genotype patterns described in the published literature on sickle cell disease and trait.
These categories reflect typical genotype patterns rather than a single universally standardized cutoff scheme. Recent transfusions, age (newborns still have high fetal hemoglobin), and pregnancy can shift the values, so interpret them in the context of your full hemoglobin panel.
| Pattern | Typical HbS % | What It Suggests |
|---|---|---|
| No HbS detected | 0% | Neither sickle cell disease nor trait |
| Sickle cell trait (HbAS) | Around 35-45% HbS, with HbA the majority | One sickle gene; usually no symptoms but reproductive implications |
| Sickle/beta-plus thalassemia or HbSC | Variable, often 50-70% HbS with reduced HbA or presence of HbC | Sickle cell disease, often milder than HbSS but still capable of crises |
| Sickle cell anemia (HbSS) or HbS/beta-zero thalassemia | Typically above 80-90% HbS with no HbA | Most severe sickle cell disease |
Compare your results within the same lab over time for the most meaningful trend. If you are on a chronic transfusion program, the goal is often to keep HbS below a specified percentage, but the exact target is set by your hematologist, not by a generic reference range.
For an initial diagnosis, a single qualitative test that detects the presence of HbS is usually definitive. The genotype does not change. But the HbS percentage does change, and that is where serial testing matters.
If you are on hydroxyurea (a medication that raises HbF and reduces sickling), starting therapy, or receiving chronic red cell transfusions, your HbS percentage should be tracked regularly to confirm the treatment is working. Newborn screening also benefits from confirmatory and follow-up testing because high fetal hemoglobin in early infancy can mask the eventual adult pattern. A reasonable cadence for someone with sickle cell disease is testing aligned with each clinic visit, typically every 3 to 6 months, with more frequent testing during transfusion programs or when therapy changes.
If you test positive for sickle cell trait and you have a partner planning children, both of you should be tested. If both partners carry HbS or another beta-globin variant such as HbC or beta-thalassemia, a genetic counselor can walk you through the risk to your children and the options available, including prenatal testing.
If your result suggests sickle cell disease, the next steps include confirmatory testing with HPLC or capillary electrophoresis and often DNA-based testing of the HBB gene to distinguish HbSS from HbS combined with beta-thalassemia. These genotypes look similar on simple tests but have different prognoses and treatment paths. A hematologist with experience in sickle cell disease should be involved early. Companion tests typically include a complete blood count with red cell indices, reticulocyte count, bilirubin, LDH (lactate dehydrogenase, a marker of cell breakdown), HbA2 and HbF quantitation, and ferritin.
A positive HbS result is not an emergency, but it is a result that should always be confirmed and contextualized. If a point-of-care or screening test detects HbS, follow up with HPLC or capillary electrophoresis at a clinical lab to quantify the percentage and identify any co-existing variants. If the pattern suggests sickle cell disease, add HBB gene sequencing to nail down the exact genotype, since HbSS, HbS/beta-zero, and HbS/beta-plus thalassemia behave differently.
For carriers, the action is reproductive counseling and family testing. For someone with disease, the action is referral to a hematologist, baseline assessment of organ function (kidneys, lungs, brain imaging in children), vaccinations, infection prophylaxis in young children, and a discussion of disease-modifying therapy. Established options include hydroxyurea, transfusions, L-glutamine, crizanlizumab, and voxelotor, with gene therapy and CRISPR-based approaches now approved as potentially curative options for selected patients.
Evidence-backed interventions that affect your Hemoglobin S level
Hemoglobin S is best interpreted alongside these tests.